These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10547469)

  • 1. Safety of home-based and office allergy immunotherapy: A multicenter prospective study.
    Hurst DS; Gordon BR; Fornadley JA; Hunsaker DH
    Otolaryngol Head Neck Surg; 1999 Nov; 121(5):553-61. PubMed ID: 10547469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
    Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
    Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of self-administered allergen immunotherapy during the buildup and maintenance phases.
    Schaffer FM; Naples AR; Ebeling M; Hulsey TC; Garner LM
    Int Forum Allergy Rhinol; 2015 Feb; 5(2):149-56. PubMed ID: 25476041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse reactions to immunotherapy in pediatric patients].
    Avila Castañón L; Lerma-Ortiz L; Velázquez Armenta Y; del Rio Navarro BE; Sienra Monge JJ
    Rev Alerg Mex; 2003; 50(5):182-6. PubMed ID: 14631589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of quality improvement measures on the delivery of allergy immunotherapy: a 2-year follow-up.
    Mattos JL; Ferguson BJ; Lee S
    Int Forum Allergy Rhinol; 2015 Jun; 5(6):513-6. PubMed ID: 25845709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
    Cardona R; Lopez E; Beltrán J; Sánchez J
    Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose dependence of efficacy but not of safety in sublingual immunotherapy.
    Frati F; Incorvaia C; Marcucci F; Sensi L; Di Cara G; Puccinelli P; Dal Bo S
    Monaldi Arch Chest Dis; 2006 Mar; 65(1):38-40. PubMed ID: 16700192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local and systemic reactions to subcutaneous allergen immunotherapy: Ten years' experience in a pediatric clinic.
    Nacaroglu HT; Erdem SB; Sumer O; Karaman S; Unsal Karkıner CS; Asilsoy S; Gunay I; Can D
    Ann Allergy Asthma Immunol; 2016 Apr; 116(4):349-53. PubMed ID: 26905639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylaxis: still a ghost behind allergen immunotherapy.
    Makatsori M; Calderon MA
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):316-22. PubMed ID: 24873937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate adverse reactions to immunotherapy.
    Can D; Demir E; Tanaç R; Gülen F; Yenigün A
    J Investig Allergol Clin Immunol; 2003; 13(3):177-80. PubMed ID: 14635467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy for treating respiratory allergy: a review on its effectiveness and suitability.
    Incorvaia C; Fuiano N; Leo G
    Clin Ter; 2010; 161(6):543-7. PubMed ID: 21181085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline serum tryptase levels and adverse reactions to injection specific immunotherapy with airborne allergens: is there a relationship?
    Asero R; Farioli L; Pastorello EA
    Int Arch Allergy Immunol; 2012; 158(3):276-80. PubMed ID: 22398453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice.
    Copenhaver CC; Parker A; Patch S
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):441-7. PubMed ID: 22018617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable immunotherapy: recommendations for safe allergen vial preparation in the office setting.
    Lay PC
    Curr Opin Otolaryngol Head Neck Surg; 2009 Jun; 17(3):223-5. PubMed ID: 19395969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety considerations in providing allergen immunotherapy in the office.
    Mattos JL; Lee S
    Curr Opin Otolaryngol Head Neck Surg; 2016 Jun; 24(3):226-30. PubMed ID: 27092905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunotherapy in Northern Israel: efficacy and safety.
    Rottem M; Egbarya A
    Isr Med Assoc J; 2014 Sep; 16(9):539-43. PubMed ID: 25351009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of specific immunotherapy to mosquito bites.
    Ariano R; Panzani RC
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):131-8. PubMed ID: 15180354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Specific immunotherapy in desensitization of allergic patients. Oral administration instead of injections? (interview by Andrea Warpakowski)].
    Grevers G
    MMW Fortschr Med; 2003 May; 145(18):18. PubMed ID: 12808815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.